Fiala

Peptide library › Metabolic & weight

Lixisenatide

Also known as Adlyxin, Lyxumia, Soliqua (with insulin glargine)

FDA-approved drugMetabolic & weight

Once-daily GLP-1 medicine for type 2 diabetes, now mainly used in a combined pen with insulin glargine.

What people use it for

What Lixisenatide does in the body

A short-acting GLP-1 receptor agonist based on exendin-4. Its strongest effect is slowing stomach emptying, which blunts the rise in blood sugar after meals, alongside boosting insulin and lowering glucagon.

Strength of evidence

Strong: the GetGoal trial programme, and the ELIXA heart safety trial, which found no increase in heart risk.

Look up the evidence

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

Who should avoid it or take extra care

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

FDA-approved in 2016. The stand-alone Adlyxin pen was discontinued in the US in 2023; it remains available combined with insulin glargine as Soliqua.

How it's taken

Route: Injection under the skin, once daily before a meal

How long it lasts (half-life): About 3 hours

Latest research & news

Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.

Keep track of Lixisenatide privately

Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.

Open Lixisenatide in Fiala How to install
Not medical advice. This page is general education. Talk to a qualified clinician before starting, stopping or changing any treatment.

More in Metabolic & weight